A Weight-Loss Shot Eased Knee Arthritis Pain — Here's What STEP 9 Actually Showed

A WOMAC pain-score drop of 41.7 points with semaglutide, versus 27.5 with placebo. That single comparison is why a weight-loss shot ended up in the arthritis headlines. The drug people know as Wegovy did something nobody marketed it for: it quieted knee pain. Not a little. A lot.

The number comes from a trial called STEP 9, published in late 2024. People who had both knee osteoarthritis and obesity got either semaglutide — the molecule sold as Wegovy in the US — or a placebo, on top of their usual care. After 68 weeks, the semaglutide group reported a much bigger drop in knee pain. That 41.7 versus 27.5 gap is the figure that made researchers sit up.

The gap is real, and it's worth understanding. The story underneath it is more careful than "the shot fixes your knees," though — so here's what the trial showed, why it probably worked, and where the line sits between a genuine finding and a headline running ahead of the science.

The surprise nobody was selling

Nobody set out to invent an arthritis drug. Semaglutide was already approved for obesity, and the question STEP 9 asked was narrower and more interesting — if you treat the obesity in someone whose knees hurt, does the knee pain follow?

Osteoarthritis is the wear-and-tear kind of arthritis, the one where cartilage thins and the joint grinds. It's the most common form, and the knee is its favorite target. For decades the playbook has been the same: lose weight, stay active, manage pain, and eventually, for some people, replace the joint. "Lose weight" has always been the advice that's easiest to give and hardest to follow.

So a trial that pairs a medication people genuinely lose weight on with a hard outcome — does your knee feel better, day to day — was always going to get attention. What it found is why the attention stuck.

The headline isn't that a weight-loss drug exists. It's that treating obesity moved a pain score that usually only budges with months of physical therapy or, eventually, surgery.

What STEP 9 actually measured

The details are the whole point here, so start with the setup.

STEP 9 enrolled 407 participants, all of them adults with obesity and clinically diagnosed knee osteoarthritis. They were randomized to weekly semaglutide or placebo, and the trial ran 68 weeks — about 16 months. Long enough to mean something.

Researchers tracked knee pain with the WOMAC index, a standard questionnaire for osteoarthritis that scores pain, stiffness, and physical function. Higher scores mean worse symptoms, so a bigger negative change is a bigger improvement. On the pain subscale, the semaglutide group improved by 41.7 points. The placebo group improved by 27.5. Both got better — placebo groups in pain trials almost always do — but semaglutide pulled clearly ahead.

Weight moved too, and that's central to the story. The semaglutide group lost an average of 13.7% of body weight over the 68 weeks. The placebo group lost 3.2%. For someone starting at 100 kg (about 220 lb), that's roughly 13.7 kg gone versus a little over 3.

And the part that arguably matters most day to day: physical function. On the SF-36 physical-function scale, the semaglutide group improved by 12.0 points, the placebo group by 6.5. That's the difference between "my knee hurts less on a chart" and "I can climb the stairs without dreading it."

A WOMAC pain change of 41.7 versus 27.5, weight down 13.7% versus 3.2%, function up 12.0 versus 6.5. Three different yardsticks, all pointing the same direction.

Why a weight drug reaches the knee

This is where it helps to think about what your knee does all day.

Your knees carry you. And the load they bear isn't your body weight at rest — it's multiplied by movement. Walking on flat ground can put several times your body weight through each knee with every step; stairs and slopes push it higher. So the math is brutal in a good way: every kilogram you don't carry is several kilograms of force the joint doesn't absorb, thousands of times a day.

Drop 13.7% of body weight and you've taken a meaningful chunk of mechanical stress off a joint that's already worn. Less force across damaged cartilage, less pain. That's the simplest, most established explanation, and it almost certainly accounts for a large share of what STEP 9 saw.

There may be more to it. Obesity isn't just extra load — it's also a low-grade inflammatory state, and osteoarthritis has an inflammatory component too. GLP-1 medications affect more than appetite, and researchers are studying whether some of the pain benefit comes from dampened inflammation rather than reduced weight alone. That part is genuinely open. The honest position right now is: load reduction is the main driver we can point to, and a direct anti-inflammatory effect is a plausible bonus that hasn't been pinned down.

STEP 9 by the numbers

A side-by-side makes the contrast easier to hold in your head.

A few notes on reading a table like this. The placebo column isn't zero, and that's normal — people in trials get attention, encouragement, and often better baseline care, so they improve. The real signal is the distance between the two columns. On every measure here, semaglutide opened a clear gap.

For context on the weight piece: in longer studies, semaglutide has produced average body-weight reductions in the mid-teens as a percentage. STEP 9's 13.7% over 68 weeks sits right in that established range, which is reassuring — the weight effect wasn't a fluke of this one trial. Just keep the two apart; they come from different trials and populations.

Was it just the weight loss?

This is the question a skeptical reader should ask, so let's take it seriously.

If almost all the pain relief traces back to weight loss, then semaglutide isn't doing anything special to the joint — it's just an effective way to get the weight off, and the knee benefits the way it would from losing weight by any route. That's not a knock. It's a clarification of what kind of finding this is.

And the evidence leans that way. The pain improvement tracked with the weight change, and weight loss is the one intervention that's been shown over and over to ease knee osteoarthritis. So the most defensible reading of STEP 9 is: the drug worked on the knee mostly by working on the weight.

The open door is whether there's a smaller, separate effect — inflammation, joint metabolism, something not fully mapped. Possibly. The trial wasn't designed to isolate that, so it can't answer it. Which is a useful reminder: a study can show a clear result and still leave the mechanism partly unsettled. STEP 9 is strong on "did it help" and modest on "exactly how."

What this result means — and what it doesn't

Worth being precise here, because this is where headlines tend to overreach.

What it means: for people who have both obesity and knee osteoarthritis, treating the obesity with semaglutide produced a measurable, clinically relevant drop in knee pain and a real gain in function over 68 weeks. That's a legitimate finding from a randomized trial. If that describes you, it's a reasonable thing to raise with your doctor.

What it does not mean:

• It is not an approved treatment for knee osteoarthritis. Semaglutide is approved for obesity (and related conditions), not as an arthritis therapy. STEP 9 is a result, not a new indication on the label.
• It does not replace the basics. Physical therapy, targeted strengthening, pain management, and staying active still matter. The trial layered semaglutide on top of usual care — it didn't swap it out.
• It is not a knee cure. Osteoarthritis is structural. Less weight eases the load and the pain; it doesn't regrow cartilage or undo the joint damage that's already there.
• It is not for everyone with knee pain. The participants had obesity. The result speaks to that group. If your knees hurt and your weight is in a healthy range, this trial isn't really about you.

The cleanest summary: STEP 9 is encouraging news for a specific group, reported responsibly. It is not a green light to treat arthritis with a weight-loss shot.

Where the lever reaches, and where it stops

If you and your doctor were to consider this, here's a grounded picture of what improves and what stays put.

Expectations are the whole game with chronic conditions. Someone who goes in expecting their knee to feel like it did at 25 will be let down. Someone who hopes for less daily pain and easier movement — stairs, getting out of a chair, a longer walk before the ache sets in — is aligned with what the trial found.

Who this is genuinely relevant for

Picture the person STEP 9 was built around. Carrying meaningful extra weight. A knee that's been diagnosed with osteoarthritis and that complains on stairs, after sitting, at the end of a long day. Maybe weighing a joint replacement someday but not there yet. For that person, the trial's headline number — a WOMAC pain change of 41.7 with semaglutide — is more than a statistic. It's a credible reason to have a fuller conversation about treating the weight, with the knee benefit as part of the calculus.

If that's not you — if your weight is already healthy and your knees still hurt — the takeaway is different. Your path runs through the standard osteoarthritis toolkit and a conversation with someone who can look at your specific joint. STEP 9 doesn't change that.

And whatever bucket you're in, the side-effect profile of GLP-1 medications is its own conversation. Nausea and other digestive effects are common, especially early on, and these drugs aren't right for everyone. "It helped knee pain in a trial" sits alongside the full picture of how a medication fits your health — not above it.

Questions worth bringing to your doctor

If this trial nudged you to ask about your own knees and weight, a few questions tend to make that appointment more useful.

Does my situation match the trial? The honest framing is "I have knee osteoarthritis and I'm carrying extra weight — does the STEP 9 result apply to someone like me?" Your doctor can tell you whether the picture fits.

What's the realistic goal? Less pain and better function are reasonable aims. A cured joint isn't on the table. Naming the goal out loud keeps expectations honest.

Where do the basics fit? Ask how physical therapy, strengthening, and activity work together with anything else you discuss. The trial added the medication to usual care — it didn't replace it, and neither should your plan.

What about the trade-offs? Side effects, cost, how long you'd stay on it, what happens if you stop. These are the questions that decide whether something good on paper is right for your life.

A short checklist if you're weighing this

You don't have to figure this out alone or all at once. A simple sequence helps.

1. Get the diagnosis clear. "My knee hurts" and "I have knee osteoarthritis" aren't the same thing. Imaging or an exam settles it.
2. Take an honest read of weight and load. If excess weight is in the picture, it's likely part of the knee story — and the most modifiable part.
3. Keep doing the basics. Movement, strengthening, and whatever pain management you already use. Don't drop them in anticipation of a single fix.
4. Bring STEP 9 to the conversation, not the pharmacy. The result is a discussion starter with a clinician about treating the weight, not a self-prescription for the joint.
5. Decide together, on the whole picture. Benefit, side effects, cost, and what you're actually trying to get back — a flight of stairs, a walk, a night without aching.

The lasting point from STEP 9 is quieter than the headlines made it sound. Treat the obesity, and the knee often gets a break — measurably, on a yardstick that usually only moves with months of effort. That's a real result, and it's a narrow one. Both of those are true at the same time, and the trial is at its most useful when you hold them together instead of picking the one that fits the headline.

The figures here come from a published, peer-reviewed trial. Whether semaglutide belongs in your own plan is a different question — one your doctor can answer with your whole health picture in front of them, not a chart in a blog post.

Start managing your GLP-1 with Blueshot

AI coaching, injection scheduling, and weight tracking in one app